Position of the Transparency Council – Omjjara (momelotinib)

At its meeting on 22 April 2025, the Transparency Council adopted position No. 46/2025 on the evaluation of the drug Omjjara (momelotinib) under drug program B.81. “Treatment of patients with Ph (-) myeloproliferative neoplasms (ICD-10: D45, D47.1)”

Publication of the position >>